John Cullity
Direktor/Vorstandsmitglied bei HaemaLogiX Pty Ltd.
Vermögen: 7 Mio $ am 30.04.2024
Profil
John Cullity is currently a Director at Theraly Fibrosis, Inc., a Non-Executive Director at HaemaLogiX Pty Ltd., a Managing Director at Biosynergy Partners LLC, and a Member at The Royal College of Physicians.
He previously worked as a Director of Health Economics at Merk Sharp & Dohme (Holdings) Pty Ltd.
and Sanofi-Aventis Healthcare Pty Ltd., a Senior Member of Business Development at Sanofi-Synthelabo, Inc., and a Principal at Torreya Partners LLC.
He also served as a Director at Ceramedix Holdings LLC and a Non-Executive Director at Race Oncology Ltd.
Dr. Cullity holds a graduate degree from the London School of Economics & Political Science, an undergraduate degree from The University of Western Australia, and an MBA from The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
5,06% | 25.08.2023 | 8 402 194 ( 5,06% ) | 7 Mio $ | 30.04.2024 |
Aktive Positionen von John Cullity
| Unternehmen | Position | Beginn |
|---|---|---|
| Biosynergy Partners LLC | Corporate Officer/Principal | 01.09.2013 |
Theraly Fibrosis, Inc.
 Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Theraly Fibrosis, Inc. operates as a commercial physical research company. The company was founded by Seulki Lee and is headquartered in Germantown, MD. | Direktor/Vorstandsmitglied | 01.09.2016 |
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Direktor/Vorstandsmitglied | 01.01.2015 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von John Cullity
| Unternehmen | Position | Ende |
|---|---|---|
| RACE ONCOLOGY LIMITED | Vorsitzender | 20.04.2023 |
| Ceramedix Holdings LLC | Direktor/Vorstandsmitglied | 01.03.2020 |
Torreya Partners LLC
 Torreya Partners LLC Investment ManagersFinance Torreya Partners LLC engages in provision of financial advisory services. The company was founded by Tim Opler and Mark Simon in 2007 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2017 |
| Sanofi-Aventis Healthcare Pty Ltd. | Corporate Officer/Principal | - |
Merk Sharp & Dohme (Holdings) Pty Ltd.
 Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Merk Sharp & Dohme (Holdings) Pty Ltd. develops, manufactures and markets drug therapies. The company was founded in 1958 and is headquartered in Macquarie Park, Australia. | Corporate Officer/Principal | - |
Ausbildung von John Cullity
| London School of Economics & Political Science | Graduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| The University of Western Australia | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RACE ONCOLOGY LIMITED | Health Technology |
| Private Unternehmen | 8 |
|---|---|
| Biosynergy Partners LLC | |
| Sanofi-Synthelabo, Inc. | Health Technology |
Merk Sharp & Dohme (Holdings) Pty Ltd.
Merk Sharp & Dohme (Holdings) Pty Ltd. Pharmaceuticals: MajorHealth Technology Merk Sharp & Dohme (Holdings) Pty Ltd. develops, manufactures and markets drug therapies. The company was founded in 1958 and is headquartered in Macquarie Park, Australia. | Health Technology |
| Sanofi-Aventis Healthcare Pty Ltd. | |
Torreya Partners LLC
Torreya Partners LLC Investment ManagersFinance Torreya Partners LLC engages in provision of financial advisory services. The company was founded by Tim Opler and Mark Simon in 2007 and is headquartered in New York, NY. | Finance |
Theraly Fibrosis, Inc.
Theraly Fibrosis, Inc. Pharmaceuticals: MajorHealth Technology Theraly Fibrosis, Inc. operates as a commercial physical research company. The company was founded by Seulki Lee and is headquartered in Germantown, MD. | Health Technology |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | Health Technology |
| Ceramedix Holdings LLC |
